この資料は医療llmの大切なデータである。
オープンソースの医療カルテ設計のテストデータでもある。後者ではデータ中心設計の事例与件である。

医工連携の医療系設計の基礎与件でもあります。

医療系設計者以外は読み飛ばしてください。

V．炎症性筋疾患診療の現状と展望
庄田宏文

引用文献 (10)

McHugh NJ, Tansley SL: Autoantibodies in myositis. Nat Rev Rheumatol 14: 290-302, 2018.
Lundberg IE: Myositis in 2016: New tools for diagnosis and therapy. Nat Rev Rheumatol 13: 74-76, 2017.
Dalakas MC: Inflammatory muscle diseases. N Engl J Med 372: 1734-1747, 2015.
Mariampillai K, et al: Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75: 1528-1537, 2018.
Pinal-Fernandez I, et al: Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis 79: 1234-1242, 2020.
Lundberg IE, et al: 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76: 1955-1964, 2017.
Aggarwal R, et al: 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Ann Rheum Dis 76: 792-801, 2017.
Tsuji H, et al: Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.
Oddis CV, et al: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65: 314-324, 2013.
Chen Z, et al: Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381: 291-293, 2019.